EGCG synergizes the therapeutic effect of irinotecan through enhanced DNA damage in human colorectal cancer cells. Issue 16 (16th June 2021)

• Record Type: Journal Article
• Authors: Wu, Wenbing; Dong, Jingying; Gou, Hui; Geng, Ruiman; Yang, Xiaolong; Chen, Dan; Xiang, Bin; Zhang, Zhengkun; Ren, Sichong; Chen, Lihong; Liu, Ji
• Is Part Of: Journal of cellular and molecular medicine. Volume 25:Issue 16(2021)
• Page Start: 7913
• Page End: 7921
• Publication Date: 2021-06-16
• Subjects: apoptosis -- autophagy -- colorectal cancer -- DNA damage -- EGCG -- irinotecan; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.16718
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Irinotecan is a kind of alkaloid with antitumour activity, but its low solubility and high toxicity limit its application. Epigallocatechin‐3‐gallate (EGCG) is one of the main bioactive components in tea. The epidemiological investigation and animal and cell experiments show that EGCG has a preventive and therapeutic effect on many kinds of tumours. Here, colorectal cancer cells RKO and HCT116 were employed, and the CCK8 proliferation test was used to screen the appropriate concentration of EGCG and irinotecan, and the effects of single and/or combined drugs on migration, invasion, DNA damage, cell cycle and autophagy of tumour cells were investigated. The results showed that EGCG combined with irinotecan (0.5 μmol L − ) not only had a stronger inhibitory effect on tumour cells than EGCG or irinotecan alone but also prevented tumour cell migration and invasion. EGCG alone did not cause DNA damage in colorectal cancer cells, but its combination with irinotecan could induce S or G2 phase arrest by inhibiting topoisomerase I to cause more extensive DNA damage. EGCG also induced apoptosis by promoting autophagy with irinotecan synergistically. These results indicated that EGCG in combination with irinotecan could be a promising strategy for colorectal cancer.